|
| |
| | Drug firm served subpoena / Genentech shares fall as feds probe |
 | | Genentech has also sponsored studies showing the drug has potential to treat rheumatoid arthritis, but the company said it hasn't tracked whether physicians are already prescribing the drug for that purpose. | | | But Genentech says some doctors recommend the drug as a frontline defense, before chemotherapy. | | | In addition, some doctors also prescribe the drug for other forms of cancer, including a type of leukemia and a more aggressive form of non- Hodgkin's lymphoma. |
|
http://www.sfgate.com/cgi-bin/article.cgi?file=/chronicle/archive/2004/10/06/BUGT194BPL19.DTL&type=business
(584 words)
|
|
| |
| | Cancer Therapy: A New Approach from BioOncology.com |
| | Genentech BioOncology™ is changing the way cancer is treated and partnering with clinicians to improve the health of patients | | | A strong program of clinical trials is crucial to the discovery of new therapies. | | | Our commitment to this goal has enabled us to make significant contributions to the understanding of cancer and to translate this understanding into targeted, biologic-based therapies. |
|
http://www.biooncology.com
(210 words)
|
|
| |
| | Genentech's Vision Thing [Fool.com: Motley Fool Take] May 25, 2005 |
| | A corollary point to consider is that Roche owns 56% of Genentech, which has developed the blockbusters Avastin and Tarceva in conjunction with Roche. | | | Now, the challenge will be to commercialize the scientific success, which means taking a more structured approach and building a platform that can effectively manage a pipeline of blockbuster drugs. | | | In fact, a Morgan Stanley analyst downgraded Eyetech and indicated that its drug went from being a billion-dollar blockbuster to roughly a third of that amount. |
|
http://www.fool.com/News/mft/2005/mft05052511.htm
(439 words)
|
|
| |
| | Genentech reports 2nd-quarter loss |
| | One analyst recently downgraded Genentech's rating after talking to some investigators in the clinical trial, but Genentech said the full results will not be released until late next quarter. | | | Biotech analyst Erin Xie of State Street Research and Management said Genentech is in a transitional period. | | | Morgan Stanley analyst Caroline Copithorne, who does not own stock in Genentech and is aware of no business deals it has with her firm, said, "Overall, the results were positive." |
|
http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2002/07/11/BU102315.DTL
(617 words)
|
|
| |
| | Stroke Research Collaborations: Genentech |
| | Genentech's commitment to innovative lytic therapy began nearly two decades ago with research into the first tissue-plasminogen activator (t-PA) to treat acute myocardial infarction (AMI). | | | Today more than ever, Genentech is fully committed to improving treatment paradigms through evidence-based medicine. | | | The organization sponsors a wide range of experimental research studies, from clinical trials, to investigations of basic biological mechanisms, and studies with animal models. |
|
http://www.lyticportfolio.com/activase/genentech_collaborations.jsp
(698 words)
|
|
| |
| | Genentech in Competition With Itself on Eye Drug - New York Times |
| | In the meantime, Genentech is beginning a clinical trial that would offer Lucentis to 5,000 patients at no cost, a move analysts say is mainly aimed at stopping doctors from using Avastin. | | | Genentech in Competition With Itself on Eye Drug | | | Genentech in Competition With Itself on Eye Drug - New York Times |
|
http://www.nytimes.com/2005/09/27/business/27place.html?ex=1285473600&en=738ed22a398e8d5c&ei=5088&partner=rssnyt&emc=rss
(986 words)
|
|
| |
| | Stroke Patient Resources from Genentech |
| | Genentech, the manufacturer of Activase, collaborated with leading physicians in the field of stroke treatment to develop a short video for stroke patients, those at risk for stroke, and their families. | | | This video is designed to educate you about stroke, stroke symptoms, and treatments available for stroke. | | | The site also offers fact sheets that address a variety of stroke-related issues and interactive tools such as the Facility Finder, which can be used to locate stroke treatment providers in your region. |
|
http://www.lyticportfolio.com/activase/patient_resources.jsp
(523 words)
|
|
| |
| | Genentech - A Biotechnology Research Company |
| | Genentech's clinical trials are crucial to our development of new therapies for unmet medical needs. | | | Genentech seeks significant returns to its stockholders based on the continuous pursuit of excellent science to develop biotherapeutics for unmet medical needs. | | | Genentech also made the list of the most admired pharmaceutical companies. |
|
http://www.gene.com
(104 words)
|
|
| |
| | Customer Profile: GENENTECH INC |
| | Genentech's initial tests of Oracle clustering technology's failover met expectations. | | | There was no loss of connectivity to the Oracle database--the key to protecting the productivity for Genentech's most critical resource--its people. | | | After a momentary pause of less than two seconds, the select statement continued without any disconnect of the client. |
|
http://www.oracle.com/pls/cis/Profiles.print_html?p_profile_id=6998
(393 words)
|
|
| |
| | Genentech halts Avastin drug study |
| | None of the other "targeted" drugs like ImClone Systems' Erbitux, AstraZeneca's Iressa or Genentech's Tarceva work the same way, and should not share the problem. | | | Initially licensed for colon cancer, it has become the first success story for attacking tumours by starving their blood supply. | | | Homepage > Research management > Genentech halts Avastin... |
|
http://www.drugresearcher.com/news/ng.asp?n=62797-genentech-avastin-vegf
(550 words)
|
|
| |
| | Executive Briefing: Genentech: Advantaged In The Middle |
| | But whether in small or large molecule dealmaking, Levinson sees Genentech largely sticking to therapies for oncology, cardiovascular, and endocrinology-with respiratory perhaps joining the group. | | | The company's management also decided to focus on three therapeutic areas: oncology, cardiovascular, and endocrinology. | | | Positive results from those studies could turn both drugs into blockbusters. |
|
http://www.windhover.com/contents/monthly/exex/e_2000800006.htm
(1053 words)
|
|
| |
| | C&EN: TODAY'S HEADLINES - GENENTECH'S CANCER TRIALS |
| | Genentech is continuing clinical studies of the angiogenesis inhibitor in colorectal and lung cancers. | | | However, expectations for Genentech's next big product, Avastin, were dashed when the firm said the cancer drug did not meet the primary clinical end point of progression-free survival. | | | The company was studying Avastin's effectiveness in relapsed metastatic breast cancer patients. |
|
http://pubs.acs.org/cen/topstory/8037/8037notw6.html
(272 words)
|
|
| |
| | IMS Health - Pharmaceutical market intelligence |
| | This report covers all of the important milestones in the development history of a drug, including phase changes, licensing activities, diseases being researched and clinical trial results. | | | A research and development profile for prostate cancer therapy, Genentech | | | A research and development profile for CDK2/cyclin A inhibitors, Genentech |
|
http://open.imshealth.com/webshop2/search.asp?search_string=Genentech
(378 words)
|
|
| |
| | OSI And Genentech Seek FDA Approval |
| | The improved survival observed in the Phase III trial that is the basis for this filing represents a potential treatment advance for both patients and physicians," said Hal Barron, M.D., Genentech's senior vice president of Development and chief medical officer. |
|
http://www.webpronews.com/business/topbusiness/wpn-54-20050502OSIAndGenentechSeekFDAApproval.html
(209 words)
|
|
| |
| | |
| | Genentech, a recognized leader in oncology therapeutics and pioneer in targeted therapies for cancer patients." | | | Perlegen Sciences, Inc. is working to provide safer and more effective drugs to consumers. | | | Daily News Central - 'There might be some way of training people [to be more resilient after cancer treatment],' says Professor Salvatore Maddi, whose area of research interest is 'hardiness,' which he defines as 'existential courage.' Despite the psychological and |
|
http://atom.pubsub.com/57/51/15c533bb3af649e40bcde4006e
(8760 words)
|
|
| |
| | Genentech: Pipeline Promise |
| | In addition to its cancer drugs Avastin and Herceptin, Genentech makes therapies that treat non-Hodgkin's lymphoma, cystic fibrosis, asthma and other conditions, either on its own or with partner companies. | | | David Molowa, an analyst at UBS Investment Research, says the drug will likely be launched in late 2006, pending additional trial results and FDA approval, and that it represents a $500 million to $1 billion opportunity for Genentech. | | | On Monday Genentech said its drug Lucentis was shown in a trial to significantly improve vision in patients with a form of age-related macular degeneration -- something no other drug has been shown to do. |
|
http://www.kiplinger.com/personalfinance/columns/picks/archive/2005/pick0524.htm
(592 words)
|
|
| |
| | Genentech "underperform" newratings.com |
| | The analysts express their concern regarding the potential competitive pressures for Genentech’s Avastin drug from Novartis&; PTK787 in the treatment of metastatic colorectal cancer. | | | Genentech quote - chart - all headlines - analyst actions | | | In addition, Genentech announced an impressive response rate and survival benefit combination data for Avastin/Tarceva in metastatic renal cell carcinoma and non-small-cell lung cancer, the analysts say. |
|
http://www.newratings.com/analyst_news/article_430453.html
(329 words)
|
|
| |
| | Novo Nordisk v. Genentech, Inc. |
| | 6 Whether Genentech proved that Novo's process was within the scope of the asserted claim is the only question we need decide in this appeal. | | | Determining whether a patent claim is infringed requires a two-step analysis: "First, the claim must be properly construed to determine its scope and meaning. | | | The work underlying the invention claimed by the present Applicants, however, represents the most facile means of achieving this result (by constructing the desired gene by combining cDNA and synthetic DNA) and represents the first instance in which the direct expression of a desired medically significant protein was clearly demonstrated. |
|
http://www.ll.georgetown.edu/Federal/judicial/fed/opinions/95opinions/95-1424.html
(3484 words)
|
|
| |
| | Genentech: About Us - Awards & Recognition |
| | Genentech Named Top Employer by ESSENCE Magazine In May 2005, Genentech was listed by ESSENCE magazine as among the top "35 Great Places to Work" for the third year in a row for its commitment to diversity in career advancement, work-life balance, representation in the workforce, and community support and involvement. | | | The awards official media sponsors were Science/AAAS, Nature, Nature Medicine, Nature Reviews Drug Discovery, Scrip World Pharmaceutical News and BioExecutive International. | | | The Cain Award recognizes individuals for outstanding preclinical research in the fields of medicinal chemistry, biochemistry, or tumor biology as related to drug discovery that has implications for the improved care of cancer patients. |
|
http://www.genetech.com/gene/about/corporate/awards/index.jsp
(1981 words)
|
|
| |
| | Bloomberg.com: Top Worldwide |
| | The stock surged 42 percent during the quarter on positive clinical trial results, helping push Genentech's market value past Amgen Inc.'s as the industry's highest. | | | Tarceva is already capturing about 95 percent of new prescriptions among doctors choosing between the two products, Clark said. | | | Before the study was released, Herceptin wasn't used to treat those patients. |
|
http://quote.bloomberg.com/apps/news?pid=10000006&sid=adHwAx8d05u8&refer=home
(837 words)
|
|
| |
| | Fool.com: More Genentech Shares On the Way (News) October 8, 1999 |
| | Valuation may be of some concern at this point, but biotechnology investors should take some time to reacquaint themselves with the public-again Genentech. | | | Roche can make the distribution decision as late as the end of Phase III trials and has agreed to fork over 50% of the development costs through Phase II and 75% of Phase III if it chooses to pick up the option for any drug. | | | Another cancer drug, the solid tumor fighting Anti-VEGF, has a bright outloook and is in Phase II trials. |
|
http://www.fool.com/news/1999/dna991008.htm
(787 words)
|
|
| |
| | Genentech Surges on Test Data |
| | Genentech and Roche said that a study of a combination therapy using Avastin plus the chemotherapy drug paclitaxel showed improved progression-free survival of metastatic breast cancer compared with chemotherapy alone. | | | This is the second time in 10 days that Genentech has reported promising clinical data for one of its cancer drugs. | | | Genentech (DNA:NYSE - commentary - research) shares surged Friday on news that the company and its Swiss partner may seek U.S. approval of their cancer drug Avastin as a treatment for breast cancer. |
|
http://www.thestreet.com/_googlen/stocks/biotech/10217801.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA
(353 words)
|
|
| |
| | SignOnSanDiego.com > News > Business -- Oceanside plant purchase shows Genentech is sailing |
| | Already a success, South San Francisco's Genentech has seen its prospects soar this year, mainly on a string of promising clinical trial results that could broaden the scope of its $3.7 billion drug franchise. | | | Genentech's top-selling drug, Rituxan, reaped $1.7 billion in revenue last year as a treatment for non-Hodgkin's lymphoma. | | | In all, Genentech has 12 approved drug products, as well as a promising pipeline of experimental drugs, notably Lucentis, a monoclonal antibody to treat age-related macular degeneration. |
|
http://www.signonsandiego.com/news/business/20050619-9999-1b19biogen.html
(961 words)
|
|
| |
| | [No title] |
| | This is the theory behind many of Genentech’s bes- known drugs, including the cancer drugs Rituxan, Avastin, and Herceptin, and asthma drug Xolair. | | | Monoclonal antibodies provide a way of targeting a drug to a particular type of cell, such as a cancerous cell, because they exploit the detailed structure of proteins called antibodies, which form part of the immune system. | | | Analysts differ in their opinions of the likely end result of the appeals process, which could take several years. |
|
http://www.redherring.com/article.aspx?a=13760
(440 words)
|
|
| |
| | Genentech - Jobs and Careers in Biotechology |
| | Featured Job: Medical Director Learn about careers as a Genentech Medical Director and meet eight Medical Directors who are turning the possibilities of biotech into improved realities for patients. | | | If you are interested in a research job at Genentech, visit our Research section to learn more about our areas of focus, technologies and scientists. | | | Diversity at Genentech "Genentech's commitment to diversity is a commitment to providing an environment where each individual is respected, honored and supported, and is rewarded on the basis of personal achievement and contribution..." |
|
http://www.gene.com/gene/careers
(384 words)
|
|
| |
| | Human Growth Hormone Web Resource - Nutropin.com |
| | Genentech provides the endocrinology community with innovative science and clinical research, excellent medical products, and a wide range of support services. | | | Since 1985, Genentech has been committed to giving patients and families safe and effective options for treatment of growth-related disorders and adult GH deficiency. | | | Genentech offers a variety of educational materials to help keep you informed about your family's health and to assist you in making healthcare choices. |
|
http://www.nutropin.com/patient/0_0_information_for_patients_and_families.jsp
(217 words)
|
|
| |
| | Genentech |
| | With its strength in all areas of the drug development process--from research and development to manufacturing and commercialization--Genentech continues to transform the possibilities of biotechnology into improved realities for patients. | | | In 2005-2006, The Breast Cancer Research Foundation's Medical Advisory Board has identified the following research grant to be designated as beneficiary of the funds from Genentech: | | | Read the important announcement about this research project presented at the May 2005 ASCO Annual Meeting! |
|
http://www.bcrfcure.org/part_onc_genentech.html
(72 words)
|
|
| |
| | Reflux Issues - Biotech Drug Shows Promise Against Ulcerative Colitis |
| | Development of the therapy started as a joint project with the biotechnology company Genentech, which has dropped out. | | | The differing results against ulcerative colitis and Crohn's disease could be explained by the subtle differences between the two conditions, Simonian said. | | | Meanwhile, researchers at Millennium are working to produce a better version of MLN02. |
|
http://www.refluxissues.com/ms/news/526316/main.html
(853 words)
|
|
| |
| | Commentary: Genentech's Lessons For Big Pharma |
| | Most other drug companies merely try to prove that their drugs will shrink tumors. | | | For cancer patients, the payoff could be big. | | | It focused primarily on cancer, one of the hardest diseases to treat. |
|
http://www.businessweek.com/magazine/content/05_19/b3932058_mz011.htm?chan=tc
(968 words)
|
|
| |
| | Lytics (Activase, Cathflo, TNKase) for Vascular Disease Conditions from Genentech |
| | Today more than ever, we are fully committed to evolving practices and improving treatment paradigms through evidence-based medicine. | | | Lytics (Activase, Cathflo, TNKase) for Vascular Disease Conditions from Genentech | | | The widest selection of safe and effective lytic products, multiple FDA approved indications, a history of first-and-only lytic advances, and a strong commitment to the future of lytic medicine are just some of the ways Genentech is taking lytics further and advancing patient care. |
|
http://www.lyticportfolio.com
(267 words)
|
|
| |
| | Genentech Halts Avastin Study |
| | Click here for more stories by Althea Chang | | | While gastrointestinal perforation is an expected side effect of the drug, it was seen in a greater-than-expected number of patients in the phase II trial. | | | The phase II trial involved patients who have not responded to at least three prior treatments, and according to Tanner, since this could be their last option, these patients aren't likely to discontinue treatment. |
|
http://www.thestreet.com/_googlen/stocks/altheachang/10244131.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA
(555 words)
|
|
| |
| | Genentech (DNA) Stock Research - Stock Quotes, Charts, News and Analysis |
| | The Company& principal activities are to discover, develop, manufacture and commercialize biotherapeutics for unmet medical needs. | | | Genentech (DNA) Stock Research - Stock Quotes, Charts, News and Analysis | | | Here's the stock research information you requested for Genentech (DNA). |
|
http://www.investorguide.com/stock.cgi?name=DNA
(288 words)
|
|
| |
| | WetFeet.com > Genentech |
| | Its research focuses on oncology, cardiovascular disease, and immunological disease. | | | Genetech's colorectal cancer treatment drug, Avastin, was FDA approved in February 2004 with high accolades from the medical community—the drug validates a previous idea for attacking cancer that scientists had been unable to put into practice until now. | | | Genentech’s dedication to research and development has resulted in a healthy product portfolio. |
|
http://www.wetfeet.com/asp/companyprofiles.asp?companypk=117
(228 words)
|
|
| |
| | [No title] |
| | Product development efforts cover a wide range of disorders or medical conditions, including cancer, respiratory disorders, cardiovascular diseases, endocrine disorders, inflammatory and immune problems, and neurological disorders. | | | Genentech, Inc. is a biotechnology company that uses human genetic information to discover, develop, manufacture and market human pharmaceuticals for significant unmet medical needs. |
|
http://lada.zacks.com/jmfr2/index.php3?t=dna&l=LEFT&w=100%&a=0&r[]=CMPDESC&r[]=ZN1C&r[]=ZN5&r[]=&c[]=000000&c[]=ffffff&c[]=000000&c[]=336699&c[]=eeeeee&d=rd&Submit=Submit&b=TRUE&ff=1&top=1&sub=1&partner=LAB
(164 words)
|
|
| |
| | Genentech - Wikipedia, the free encyclopedia |
| | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. | | | Genentech was named one of the 100 Best Companies for Working Mothers in 2004 by Working Mothers magazine. | | | One of its founders, Dr. Herbert W. Boyer was one of two scientists who pioneered the scientific field of recombinant DNA technology (the company's ticker symbol reflects Boyer's contribution to the field). |
|
http://en.wikipedia.org/wiki/Genentech
(431 words)
|
|
| |
| | USATODAY.com - Genentech stock jumps as new cancer drug gets OK |
| | Avastin, developed by South San Francisco-based Genentech (DNA), was approved for advanced colorectal cancer and for patients who haven't received other chemotherapy, according to the Food and Drug Administration. | | | Avastin's major side effect, hypertension, can be treated with high blood pressure drugs, says Sue Hellman, chief medical officer at Genentech. | | | Genentech stock jumps as new cancer drug gets OK |
|
http://www.usatoday.com/money/industries/health/drugs/2004-02-26-cancer-drug_x.htm
(453 words)
|
|
| |
| | A Peek at Genentech's Pipeline |
| | What investors may not know, however, is that Genentech has made significant investments in developing drugs to treat many other diseases beyond cancer. | | | Q: Genentech recently announced positive trial data for Lucentis, a drug to treat age-related macular degeneration (AMD). | | | Q: Genentech recently announced five successful phase-three trials, with drugs to treat breast cancer, AMD, and lung cancer. |
|
http://businessweek.com/technology/content/jun2005/tc20050622_0540_tc057.htm
(1145 words)
|
|
| |
| | Genentech no stranger to San Diego North County Times - North San Diego and Southwest Riverside County columnists |
| | Genentech's biggest problem was the lack of a "blockbuster" drug, the kind a large pharmaceutical company would covet. | | | "Genentech was the first company to really focus on biotech, and it was so dominating in terms of its science, its capabilities, the quality of the work it was doing." | | | Lyons, who now lives in Del Mar, said Genentech's early scientists worked fanatically not so much out of a desire to make money, but because they were given intellectually interesting work. |
|
http://www.nctimes.com/articles/2005/06/26/business/news/10_35_076_25_05.txt
(1747 words)
|
|
| |
| | Experimental Lucentis Drug is Reported to Restore Vision of Patients with Age-Related Macular Degeneration - Press |
| | New York NY - Lighthouse International, a leading resource worldwide in overcoming the challenges of vision impairment, congratulates Genentech on the positive results of its one-year clinical trial for a new treatment called Lucentis for the severe (wet) form of age-related macular degeneration (AMD). | | | Lighthouse International Applauds Genentech for Its Promising One-Year Clinical Trial Results | | | In a statement released by Genentech, it was revealed that patients with the wet type of AMD who received Lucentis had an average gain of seven letters on standard eye chart, compared with a 10.5 - letter loss for those given a placebo. |
|
http://www.lighthouse.org/press/pr_genentech.htm
(294 words)
|
|
| |
| | Chiron Corp. v. Genentech, Inc. |
| | Because Genentech’s arguments regarding claim construction are alternative grounds for affirming the verdict, Bailey, 292 F.3d 1360, this court proceeds on the premise that the claim construction is correct. | | | The jury determined that Genentech proved by clear and convincing evidence that none of the applications satisfy both the written description and the enablement requirement for the subject matter in the ’561 patent’s claims. | | | As a precaution, Genentech posits a “cross-appeal” on claim construction in the event this court reverses the denials of Chiron’s post-trial motions. |
|
http://www.ll.georgetown.edu/federal/judicial/fed/opinions/03opinions/03-1158.html
(6987 words)
|
|
| |
| | ARCHIBUS - Genentech Success Story |
| | Furthermore, the system was not integrated with other systems around the company. | | | Because Genentech's facilities automation information is used primarily for strategic planning purposes, the need for integration was one of the primary criteria in choosing a new system. | | | Hutchins and his planning group decided to interview other corporate departments to learn right up front what their requirements would be. |
|
http://www.archibus.com/success/genentech.htm
(844 words)
|
|
| |
| | Markets: Quote Snapshot |
| | Genentech seeks FDA okay for eye drug (CNNMoney.com) | | | Genentech Inc. The Group's principal activities are to discover, develop, manufacture and commercialize biotherapeutics for unmet medical needs. | | | Biotechs may be a good bet for 2006 (CNNMoney.com) |
|
http://money.cnn.com/quote/snapshot/snapshot.html?symb=DNA
(281 words)
|
|
| |
| | Working Mother Media: Working Mother Magazine |
| | The research company is also helping to nurture tomorrow's leaders through its Genentech Scholars program, which offers financial aid, paid internships and mentoring to college students interested in biotechnology. | | | Executives at Genentech like to say that respect for employees is in their genes, and a look at the numbers bears it out. | | | In 2003, 11 of the 15 participants in the program were women. |
|
http://www.workingmother.com/genentech.html
(239 words)
|
|
| |
| | Genentech Stock Price (DNA), Stock Quotes, Charts, Trades & Market News. |
| | Genentech Submits Supplemental Biologics License Application for Avastin(R) in Relapsed Metastatic Colorectal Cancer | | | A biotechnology company that discovers, develops, manufactures, and commercializes multiple biotherapeutic and biotechnology products and license several additional products for significant unmet medical needs. | | | Genentech Submits Biologics License Application for FDA Review of Lucentis(TM) in Wet Age-Related Macular Degeneration |
|
http://www.advfn.com/quote_genentech_nyse_dna.html
(337 words)
|
|
|
